Profile
Sector:
HealthcareCountry:
CanadaIPO:
08 June 2018Website:
http://www.fsdpharma.comNext earnings report:
19 July 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 05 Jul 2024 23:58:27 GMTDividend
Analysts recommendations
Institutional Ownership
HUGE Latest News
Targeting the Approximate $22 Billion Multiple Sclerosis Drug Treatment Market TORONTO, ON / ACCESSWIRE / August 15, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders, is pleased to announce that its late breaking abstract about Phase 1 first-in-human data on Lucid-MS (Lucid-21-302) was selected for presentation at the upcoming MSMilan 2023 - 9th Joint ECTRIMS-ACTRIMS meeting scheduled for October 11-13, 2023. Lucid-MS is a potential drug candidate for multiple sclerosis (MS) targeting demyelination, the loss of the protective myelin sheath, in the central nervous system.
TORONTO--(BUSINESS WIRE)---- $HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, today announced Mr. Zeeshan Saeed, President and Executive Co-Chairman, and Dr. Lakhsmi Kotra, Executive Director and CEO Lucid Psycheceuticals, will present and host one-on-one meetings wit.
What type of business is FSD Pharma?
FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD-201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also focuses on Lucid-PSYCH, a psychoactive molecule identified for the potential treatment of neuropsychiatric disorders, such as depressive disorder; and Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. FSD Pharma Inc. was founded in 1998 and is headquartered in Toronto, Canada.
What sector is FSD Pharma in?
FSD Pharma is in the Healthcare sector
What industry is FSD Pharma in?
FSD Pharma is in the Drug Manufacturers - Specialty & Generic industry
What country is FSD Pharma from?
FSD Pharma is headquartered in Canada
When did FSD Pharma go public?
FSD Pharma initial public offering (IPO) was on 08 June 2018
What is FSD Pharma website?
https://www.fsdpharma.com
Is FSD Pharma in the S&P 500?
No, FSD Pharma is not included in the S&P 500 index
Is FSD Pharma in the NASDAQ 100?
No, FSD Pharma is not included in the NASDAQ 100 index
Is FSD Pharma in the Dow Jones?
No, FSD Pharma is not included in the Dow Jones index
When does FSD Pharma report earnings?
The next expected earnings date for FSD Pharma is 19 July 2024